Archives — August 2017 back to current month (11)
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.
Medical Cannabis Innovator Set to Go Public (08/18/2017)
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21.
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."
Maxim Raises Target Price of Biotech Company (08/16/2017)
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
Cell Therapy for Melanoma Impresses in
Phase 2 (08/09/2017)
Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8.
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities.
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth.
|"As of Q3/17E, PMN had $3.3M in cash and zero debt on its balance sheet; we are maintaining our Speculative Buy rating."|
|"VIVE raised its outlook for 2017 revenues from $14M to $15–16M."|
|"We continue to be positive about DRRX's story."|